Andrew D.C. LaFrence - Mar 15, 2022 Form 4 Insider Report for Vyant Bio, Inc. (VYNT)

Signature
/s/ Andrew LaFrence
Stock symbol
VYNT
Transactions as of
Mar 15, 2022
Transactions value $
$0
Form type
4
Date filed
3/17/2022, 04:15 PM
Previous filing
Dec 29, 2021
Next filing
Jul 18, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VYNT Stock option (right to buy) Award $0 +110K $0.00 110K Mar 15, 2022 Common Stock 110K $1.00 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option shall become exercisable with respect to twenty five percent (25%) of the shares underlying the option upon the date of grant, with respect to thirty seven and a half percent (37.5)% upon the filing by the Company of an Investigational New Drug Application ("IND") with the U.S. Food and Drug Administration ("FDA") for a New Chemical Entity ("NCE") candidate to treat Rett Syndrome and with respect to the remaining thirty seven and a half percent (37.5)% upon the filing by the Company of an IND with the FDA for an NCE candidate to treat CDKL5 Deficiency Disorders; provided that the participant remains a service provider to the Company through each applicable vesting date.